Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05533463 trial: what clinicians have said so far
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- NCT05533463 ↗
- Active, not recruiting
- Jiangsu HengRui Medicine Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05533463 (HRS-4642 in advanced KRAS G12D-mutant solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05533463 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I Study to Evaluate the Safety ,Tolerability, and Pharmacokinetics of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Advanced KRAS G12D Mutant Solid Tumors
- Interventions
- HRS-4642
- Arms
- HRS-4642 · Experimental
- Enrollment
- 102
- Primary outcomes
- Safety endpoints: adverse events(AEs), serious adverse events（SAEs）.
- Dose Limited Toxicity(DLT)
- Maximum tolerated dose (MTD)
- RP2D
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Start
- Sep 21, 2022
- Primary completion
- Jun 25, 2024
- Results posted
- No
- Registry record
- NCT05533463 · updated Sep 8, 2025
Publications
linked from the registry- Zhou C, Li C, Luo L, Li X, Jia K, He N, Mao S, Wang W, Shao C, Liu X, Huang K, Yu Y, Cai X, Chen Y, Dai Z, Li W, Yu J, Li J, Shen F, Wang Z, He F, Sun X, Mao R, Shi W, Zhang J, Jiang T, Zhang Z, Li F, Ren S. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8. doi: 10.1016/j.ccell.2024.06.001. Epub 2024 Jun 27. PubMed 38942026